Edwards Lifesciences is a multinational American company that focuses on heart valves and hemodynamic monitoring.
The company, based in Irvine, California, is publicly listed on the New York Stock Exchange under the stock ticker symbol ‘EW’.
It mainly produces technologies in the areas of structural heart disease and critical care monitoring. Edwards is the world’s number one manufacturer of heart valves and repair products used to replace or repair a patient’s diseased or defective heart valve. It is also a global leader in hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.
Edwards Lifesciences has two primary product areas:
Heart Valve Technologies – offers tissue replacement heart valves and valve repair products including Edwards’ family of PERIMOUNT bovine pericardial tissue valves and offers technologies designed for the replacement of heart valves without surgery.
Critical Care Technologies – develops and markets Swan-Ganz advanced hemodynamic monitoring devices, monitoring platforms to simplify decision-making in the hospital environment, provides evidence-based medicine programs such as Sepsis Management and Enhanced Surgical Recovery Programs, and vascular therapies products (such as Fogarty catheters).
Overview
- Chairman and CEO: Michael A. Mussallem
- CFO: Scott B. Ullem
- Type: Public
- Industry: Medical Devices
- Publicly listed on the New York Stock Exchange (NYSE)
- NYSE stock ticker symbol: EW
- S&P 500 Component
- Revenue: $2.045 billion USD (2013)
- Net income: $391.7 million USD (2013)
- Diluted earnings per share: $3.44 USD (2013)
- Employees: 8,600 (2013)
- Corporate headquarters: One Edwards Way, Irvine, California 92614, USA
- Corporate contact number: (949) 250-2500
- Investor relations contact number: (949) 250-2806
- Investor relations email address: [email protected]
- Website: http://www.edwards.com/
| Operating data (in $ millions) | 2013 | 2012 |
| Net sales | $2,045.5 | $1,899.6 |
| Cost of products sold | $522.4 | $494.6 |
| Gross profit | $1,523.1 | $1,405.0 |
| Selling, general and administrative expenses | $745.6 | $705.3 |
| Research and development expenses | $323.0 | $291.3 |
| Income before provision for income taxes | $515.3 | $391.1 |
| Provision for income taxes | $123.6 | $97.9 |
| Net income | $391.7 | $293.2 |
| Balance sheet data (in $ millions) | ||
| Total assets | $34,841 | $32,818 |
| Long-term debt | $9,741 | $7,359 |
| Total stockholders’ equity | $18,671 | $17,113 |
| Cash flow data (in $ millions) | ||
| Net cash provided by operating activities | $472.7 | $362.1 |
| Net cash used in investing activities | $(412.7) | $(78.8) |
| Net cash provided by (used in) financing activities | $34.9 | $(155.6) |
| Cash and cash equivalents at end of period | $420.4 | $310.9 |
| Common share data (in $) | ||
| Basic earnings (loss) per common share | $3.51 | $2.55 |
| Diluted earnings (loss) per common share | $3.44 | $2.48 |
Source: “Edwards Lifesciences Corporation 2013 Annual Report”